Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300

January 29, 2024 By The ASCO Post Staff

Dominik P. Modest, MD, of Charité-Universitätsmedizin Berlin, discusses phase III study findings showing sotorasib plus panitumumab vs trifluridine/tipiracil or regorafenib benefits patients with chemorefractory metastatic colorectal cancer in terms of improved clinical outcomes and better self-reported quality of life (Abstract 10).

Related Content